Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study: Songji Choi, Se Hyun Kim, Sejoon Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee; Cancer Res Treat. 2025;57(1):70-82. Published online August 7, 2024; DOI: https://doi.org/10.4143/crt.2024.046

Abstract PDF Supplementary Material PubReader ePub

Purpose
Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.
Materials and Methods
Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed.
Results
In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT.
Conclusion
Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.

Citations

Citations to this article as recorded by

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics
Clelia Madeddu, Eleonora Lai, Manuela Neri, Elisabetta Sanna, Giulia Gramignano, Sonia Nemolato, Mario Scartozzi, Sabrina Giglio, Antonio Macciò
International Journal of Molecular Sciences.2025; 26(5): 2232. CrossRef

1,538 View
156 Download
1 Web of Science
1 Crossref

Pediatric cancer

The Role of Early and Delayed Surgery for Infants with Congenital Brain Tumors: Jong Seok Lee, Ji Yeoun Lee, Kyung Hyun Kim, Sung-Hye Park, Eun Jung Koh, Seung-Ki Kim, Ji Hoon Phi; Cancer Res Treat. 2024;56(3):909-919. Published online December 28, 2023; DOI: https://doi.org/10.4143/crt.2023.1174

Abstract PDF Supplementary Material PubReader ePub: Purpose
The present study aimed to evaluate the role of early and delayed surgery in congenital brain tumors and analyze the clinical outcomes of infantile brain tumors.
Materials and Methods
We performed a retrospective cohort study on 69 infantile brain tumors at a single institution from January 2008 to June 2023. Outcomes were assessed as early mortality (within 30 days following surgery) to evaluate the risk of early surgery in congenital brain tumors. Outcomes of recurrence and overall survival were analyzed in infantile brain tumors.
Results
Surgery-related early mortality appeared to occur in young and low-body-weight patients. Cut-off values of age and body weight were found to be 1.3 months and 5.2 kg to avoid early mortality. Three patients (3/10, 30%) showed early mortality in the early surgery group, and early mortality occurred in one patient (1/14, 7.14%) in the delayed surgery group, whose tumor was excessively enlarged. Younger age at diagnosis (< 3 months of age; hazard ratios [HR], 7.1; 95% confidence intervals [CI], 1.4 to 35.6; p=0.018) and leptomeningeal seeding (LMS; HR, 30.6; 95% CI, 3.7 to 253.1; p=0.002) were significant independent risk factors for high mortality in infantile brain tumors.
Conclusion
We suggest delaying surgery until the patient reaches 1.3 months of age and weighs over 5.2 kg with short-term imaging follow-up unless tumors grow rapidly in congenital brain tumors. Younger ages and the presence of LMS are independent risk factors for high mortality in infantile brain tumors.

2,799 View
101 Download

Palliative medicine

A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients: Yu Jung Kim, Yusuke Hiratsuka, Sang-Yeon Suh, Beodeul Kang, Si Won Lee, Hong-Yup Ahn, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee; Cancer Res Treat. 2022;54(2):621-629. Published online July 12, 2021; DOI: https://doi.org/10.4143/crt.2021.483

Abstract PDF PubReader ePub

Purpose
We aimed to develop a prognostic model to assist palliative care referral at least 3 months before death in advanced cancer patients treated at an outpatient medical oncology clinic.
Materials and Methods
In this prospective cohort study, a total of 200 patients were enrolled at a tertiary cancer center in South Korea. The major eligibility criterion was an expected survival of less than a year as estimated by their oncologists. We analyzed the influences of known prognostic factors along with chemotherapy status, mid-arm circumference, and triceps skinfold thickness on survival time.
Results
The mean age of the patients was 64.5 years, 36% were female, and the median survival time was 7.6 months. In the multivariate analysis, we found 6 significant factors related to poor survival: a poor Eastern Cooperative Oncology Group (ECOG) performance status (≥2), not undergoing chemotherapy, anorexia, a low lymphocyte level (<12%), a high lactate dehydrogenase (LDH) level (≥300 IU/L), and a low mid-arm circumference (<23 cm). We developed a prognostic model (score, 0-8.0) to predict 3-month survival based on the multivariate analysis. Patients who scored ≥4.0 points had a short survival of less than 3 months (p<0.001). The discriminating ability of the prognostic model using the area under the receiver operating characteristic curve (AUC) was 0.88.
Conclusion
The prognostic model using ECOG performance status, chemotherapy status, anorexia, lymphocytes, LDH, and mid-arm circumference can predict 3-month survival in medical oncology outpatients. It can alert oncologists to refer patients to palliative care specialists before it is too late.

Citations

Citations to this article as recorded by

Clinicians’ Prediction of Survival Is Most Useful for Palliative Care Referral
Eun Hee Jung, Yusuke Hiratsuka, Sang-Yeon Suh, Seok-Joon Yoon, Beodeul Kang, Si Won Lee, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Keun-Wook Lee, Yu Jung Kim
Palliative Medicine Reports.2024; 5(1): 365. CrossRef

8,310 View
173 Download
3 Web of Science
1 Crossref

Lung and Thoracic cancer

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Hyojin Kim, Hyun Jung Kwon, Eun Sun Kim, Soohyeon Kwon, Kyoung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Jin-Haeng Chung; Cancer Res Treat. 2022;54(2):424-433. Published online July 7, 2021; DOI: https://doi.org/10.4143/crt.2021.583

Abstract PDF Supplementary Material PubReader ePub

Purpose
Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non–small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually.
Materials and Methods
This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed.
Results
Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832).
Conclusion
The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies.

Citations

Citations to this article as recorded by

Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins
Chuanhao Tang, Zaizai Dong, Shi Yan, Bing Liu, Zhiying Wang, Long Cheng, Feng Liu, Hong Sun, Yimeng Du, Lu Pan, Yuhao Zhou, Zhiyuan Jin, Libo Zhao, Nan Wu, Lingqian Chang, Xiaojie Xu
Biosensors and Bioelectronics.2025; 267: 116748. CrossRef
Exploring the ferroptosis-related gene lipocalin 2 as a potential biomarker for sepsis-induced acute respiratory distress syndrome based on machine learning
Jiayi Zhan, Junming Chen, Liyan Deng, Yining Lu, Lianxiang Luo
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(4): 167101. CrossRef
Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial
Cheol-Kyu Park, Ha Ra Jun, Hyung-Joo Oh, Ji-Young Lee, Hyun-Ju Cho, Young-Chul Kim, Jeong Eun Lee, Seong Hoon Yoon, Chang Min Choi, Jae Cheol Lee, Sung Yong Lee, Shin Yup Lee, Sung-Min Chun, In-Jae Oh
Cells.2023; 12(9): 1246. CrossRef
Unveiling the role of regulatory T cells in the tumor microenvironment of pancreatic cancer through single-cell transcriptomics and in vitro experiments
Wei Xu, Wenjia Zhang, Dongxu Zhao, Qi Wang, Man Zhang, Qiang Li, Wenxin Zhu, Chunfang Xu
Frontiers in Immunology.2023;[Epub] CrossRef
Facilitating “Omics” for Phenotype Classification Using a User-Friendly AI-Driven Platform: Application in Cancer Prognostics
Uraquitan Lima Filho, Tiago Alexandre Pais, Ricardo Jorge Pais
BioMedInformatics.2023; 3(4): 1071. CrossRef
Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review)
Mo Cheng, Xiufeng Zheng, Jing Wei, Ming Liu
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef

8,200 View
222 Download
12 Web of Science
6 Crossref

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies: Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee; Cancer Res Treat. 2020;52(1):284-291. Published online July 23, 2019; DOI: https://doi.org/10.4143/crt.2019.200

Abstract PDF PubReader ePub

Purpose
Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261).
Materials and Methods
Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR).
Results
In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%).
Conclusion
Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.

Citations

Citations to this article as recorded by

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
S.-H. Lee, J. Menis, T.M. Kim, H.R. Kim, C. Zhou, S.A. Kurniawati, K. Prabhash, H. Hayashi, D.D.-W. Lee, M.S. Imasa, Y.L. Teh, J.C.-H. Yang, T. Reungwetwattana, V. Sriuranpong, C.-E. Wu, Y. Ang, M. Sabando, M. Thiagarajan, H. Mizugaki, V. Noronha, M. Yuli
ESMO Open.2024; 9(12): 103996. CrossRef
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
Valerio Nardone, Caterina Romeo, Emma D’Ippolito, Pierpaolo Pastina, Maria D’Apolito, Luigi Pirtoli, Michele Caraglia, Luciano Mutti, Giovanna Bianco, Antonella Consuelo Falzea, Rocco Giannicola, Antonio Giordano, Pierosandro Tagliaferri, Claudia Vincigue
La radiologia medica.2023; 128(3): 316. CrossRef
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
Mingjun Rui, Zijing Wang, Zhengyang Fei, Yao Wu, Yingcheng Wang, Lei Sun, Ye Shang, Hongchao Li
Frontiers in Pharmacology.2022;[Epub] CrossRef
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
Anwen Xiong, Shengxiang Ren, Huaimin Liu, Liyun Miao, Lei Wang, Jianhua Chen, Wei Li, Runpu Li, Xiang Wang, Zhiwei Lu, Donglin Wang, Xiaohong Wu, Zhihua Liu, Ligang Xing, Yimin Mao, Chunling Liu, Aiping Zeng, Hongrui Niu, Yingying Du, Yuping Sun, Yueyin P
Journal of Thoracic Oncology.2022; 17(10): 1216. CrossRef
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel
International Journal of Molecular Sciences.2021; 22(2): 593. CrossRef

9,712 View
305 Download
6 Web of Science
5 Crossref

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer: Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo; Cancer Res Treat. 2017;49(2):416-422. Published online July 28, 2016; DOI: https://doi.org/10.4143/crt.2016.121

Abstract PDF PubReader ePub

Purpose
The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer.
Materials and Methods
Patients were treated with irinotecan 65 mg/m² and cisplatin 30 mg/m² on days 1 and 8 of each 21-day treatment cycle. The primary endpoint was response rate, and secondary endpoints were survival, duration of response, initial metabolic response rate, and toxicity.
Results
A total of 27 patients with squamous cell histology were enrolled in the study. The median age of the patients was 61 years. The objective response rate of the 20 patients in the perprotocol group was 30.0% (90% confidence interval [CI], 13.2 to 46.9). The median follow-up duration was 10.0 months, and the median progression-free survival and overall survival were 4.5 months (95% CI, 1.6 to 6.2) and 8.8 months (95% CI, 4.7 to 10.5), respectively. Four of 13 patients (30.8%) evaluated showed initial metabolic response. The median duration of response for partial responders was 5.0 months (range, 3.4 to 8.0 months). The following grade 3/4 treatment-related hematologic toxicities were reported: neutropenia (40.7%), anaemia (22.2%), and thrombocytopenia (7.4%). Two patients experienced febrile neutropenia. The most common grade 3/4 non-hematologic toxicities were asthenia (14.8%) and diarrhoea (11.1%).
Conclusion
Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer.

Citations

Citations to this article as recorded by

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
Xichao Dai, Leilei Tao, Jinqiu Wang, Wenjuan Wu, Weigang Bian, Xichun Dai, Surong Chen
Cancer Medicine.2023; 12(15): 16108. CrossRef
Cisplatin-based combination therapy for cancer
Minerva, Amrita Bhat, Sonali Verma, Gresh Chander, Rajeshwer Singh Jamwal, Bhawani Sharma, Audesh Bhat, Taruna Katyal, Rakesh Kumar, Ruchi Shah
Journal of Cancer Research and Therapeutics.2023; 19(3): 530. CrossRef
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
Xiaokun Li, Lingmin Chen, Siyuan Luan, Jianfeng Zhou, Xin Xiao, Yushang Yang, Chengyi Mao, Pinhao Fang, Longqi Chen, Xiaoxi Zeng, Huile Gao, Yong Yuan
Seminars in Cancer Biology.2022; 86: 873. CrossRef
Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
Zhihuang Hu, Si Sun, Xinmin Zhao, Hui Yu, Xianghua Wu, Jialei Wang, Jianhua Chang, Huijie Wang
The Oncologist.2022; 27(4): 253. CrossRef
Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
Tianhui Wei, Wenqi Ti, Qingxu Song, Yufeng Cheng
Current Oncology.2022; 29(5): 2920. CrossRef
Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells
Laura Valdez, Benxu Cheng, Daniela Gonzalez, Reanna Rodriguez, Paola Campano, Andrew Tsin, Xiaoqian Fang
Oncotarget.2022; 13(1): 642. CrossRef
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect
Jiyun Lee, Binnari Kim, Hyun Ae Jung, Yoon La Choi, Jong-Mu Sun
Cancer Immunology, Immunotherapy.2021; 70(5): 1203. CrossRef
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Paul B Tchounwou, Shaloam Dasari, Felicite K Noubissi, Paresh Ray, Sanjay Kumar
Journal of Experimental Pharmacology.2021; Volume 13: 303. CrossRef
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang, Jing Huang
Thoracic Cancer.2021; 12(9): 1373. CrossRef
Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer
Mahsa Shahriari, Seyed Mohammad Taghdisi, Khalil Abnous, Mohammad Ramezani, Mona Alibolandi
Journal of Controlled Release.2021; 335: 369. CrossRef
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
Min Liu, Qingqing Jia, Xiaolin Wang, Changjiang Sun, Jianqi Yang, Yanliang Chen, Ying Li, Lingfeng Min, Xizhi Zhang, Caiyun Zhu, Johannes Artiaga Gubat, Yong Chen
Anti-Cancer Drugs.2020; 31(4): 403. CrossRef
Jiawei Xianglian Decoction (JWXLD), a Traditional Chinese Medicine (TCM), Alleviates CPT‐11‐Induced Diarrhea in Mice
Jinhua Lu, Zechen Lin, Siyu Huang, Yiwei Shen, Jing Jiang, Shengyou Lin, Oliver Micke
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef
Treatment of esophageal cancer with multiple liver metastases: a case experience of sustained complete response
Jiangfang Wang, Chaoyang Xu
Journal of International Medical Research.2020;[Epub] CrossRef
Development of chemotherapeutics for unresectable advanced esophageal cancer
Hiroshi Imazeki, Ken Kato
Expert Review of Anticancer Therapy.2020; 20(12): 1083. CrossRef
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
Bo Zhang, Ling Qi, Xi Wang, Jianping Xu, Yun Liu, Lan Mu, Xingyuan Wang, Lidan Bai, Jing Huang
Cancer Communications.2020; 40(12): 711. CrossRef
Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
Hidekazu Hirano, Ken Kato
Japanese Journal of Clinical Oncology.2019; 49(5): 412. CrossRef
Carboxylesterase and UDP‐glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra‐performance liquid chromatography–mass spectrometry analysis
Yifeng Qin, An Kang, Guisheng Zhou, Huan Wang, Wei Wei, Yujie Cao, Yanyan Chen, Jing Wang, Yajun Shi, Yuping Tang, Jianqin Jiang
Biomedical Chromatography.2018;[Epub] CrossRef
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D. N
Biochemical and Biophysical Research Communications.2018; 505(3): 733. CrossRef
Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy
Yi-Han Chiu, Shih-Hsien Hsu, Hsiao-Wei Hsu, Kuo-Chin Huang, Wangta Liu, Chang-Yi Wu, Wei-Pang Huang, Jeff Chen, Bing-Hung Chen, Chien-Chih Chiu
International Journal of Oncology.2018;[Epub] CrossRef
ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PNCA
Xin-Fang Hou, Lin-Ping Xu, Hai-Yan Song, Shuai Li, Chen Wu, Ju-Feng Wang
World Journal of Gastroenterology.2017; 23(10): 1796. CrossRef
Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer
Bin Wei, Jiru Wang, Xiaohui Zhang, Zhaoye Qian, Jingjing Wu, Yuan Sun, Qin Han, Li Wan, Jing Zhu, Yong Gao, Xiaofei Chen
Oncology Letters.2017;[Epub] CrossRef

12,184 View
272 Download
27 Web of Science
22 Crossref

Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer: Eunyoung Lee, Sung-Bum Kang, Sang Il Choi, Eun Ju Chun, Min Jeong Kim, Duck-Woo Kim, Heung-Kwon Oh, Myong Hoon Ihn, Jin Won Kim, Soo-Mee Bang, Jeong-Ok Lee, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee; Cancer Res Treat. 2016;48(3):978-989. Published online November 17, 2015; DOI: https://doi.org/10.4143/crt.2015.311

Abstract PDF PubReader ePub

Purpose
Pharmacologic thromboprophylaxis is routinely recommended for Western cancer patients undergoing major surgery for prevention of venous thromboembolism (VTE). However, it is uncertainwhetherroutine administration of pharmacologic thromboprophylaxis is necessary in all Asian surgical cancer patients. This prospective study was conducted to examine the incidence of and risk factors for postoperative VTE in Korean colorectal cancer (CRC) patients undergoing major abdominal surgery. Materials and Methods This study comprised two cohorts, and none of patients received perioperative pharmacologic thromboprophylaxis. In cohort A (n=400), patients were routinely screened for VTE using lower-extremity Doppler ultrasonography (DUS) on postoperative days 5-14. In cohort B (n=148), routine DUS was not performed, and imaging was only performed when there were symptoms or signs that were suspicious for VTE. The primary endpoint was the VTE incidence at 4 weeks postoperatively in cohort A.
Results
The postoperative incidence of VTE was 3.0% (n=12) in cohort A. Among the 12 patients, eight had distal calf vein thromboses and one had symptomatic thrombosis. Age ≥ 70 years (odds ratio [OR], 5.61), ≥ 2 comorbidities (OR, 13.42), and white blood cell counts of > 10,000/μL (OR, 17.43) were independent risk factors for postoperative VTE (p < 0.05). In cohort B, there was one case of VTE (0.7%). Conclusion The postoperative incidence of VTE, which included asymptomatic cases, was 3.0% in Korean CRC patients who did not receive pharmacologic thromboprophylaxis. Perioperative pharmacologic thromboprophylaxis should be administered to Asian CRC patients on a riskstratified basis.

Citations

Citations to this article as recorded by

The 2024 Korean Enhanced Recovery After Surgery (ERAS) guidelines for colorectal cancer: a secondary publication
Kil-yong Lee, Soo Young Lee, Miyoung Choi, Moonjin Kim, Ji Hong Kim, Ju Myung Song, Seung Yoon Yang, In Jun Yang, Moon Suk Choi, Seung Rim Han, Eon Chul Han, Sang Hyun Hong, Do Joong Park, Sang-Jae Park
Annals of Coloproctology.2025; 41(1): 3. CrossRef
Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis
Danielle Carole Roy, Tzu-Fei Wang, Ronda Lun, Amin Zahrai, Ranjeeta Mallick, Dylan Burger, Gabriele Zitikyte, Steven Hawken, Philip Wells
Thrombosis and Haemostasis.2024; 124(12): 1117. CrossRef
Venous thromboembolism among Asian populations with localized colorectal cancer undergoing curative resection: is pharmacological thromboprophylaxis required? A systematic review and meta-analysis
Shih Jia Janice Tan, Emile Kwong-Wei Tan, Yvonne Ying Ru Ng, Rehena Sultana, John Carson Allen, Isaac Seow-En, Ronnie Mathew, Aik Yong Chok
Annals of Coloproctology.2024; 40(3): 200. CrossRef
The 2024 Korean Enhanced Recovery After Surgery guidelines for colorectal cancer
Kil-yong Lee, Soo Young Lee, Miyoung Choi, Moonjin Kim, Ji Hong Kim, Ju Myung Song, Seung Yoon Yang, In Jun Yang, Moon Suk Choi, Seung Rim Han, Eon Chul Han, Sang Hyun Hong, Do Joong Park, Sang-Jae Park
Annals of Clinical Nutrition and Metabolism.2024; 16(2): 22. CrossRef
Low prevalence of deep vein thrombosis among colorectal cancer patients undergoing surgery in Taiwan: A prospective cross-sectional study
Hsuan-Yu Lin, Ting-Ming Huang, Ching-Yeh Lin, Ming-Ching Shen
Asian Journal of Surgery.2023; 46(3): 1426. CrossRef
Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study
Minsu Kang, Koung Jin Suh, Ji-Won Kim, Ja Min Byun, Jin Won Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Yu Jung Kim, Se Hyun Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee, Pal Bela Szecsi
PLOS ONE.2022; 17(1): e0261671. CrossRef
Application of venous thromboembolism prophylaxis program in patients with colorectal cancer using the enhanced recovery after surgery protocol
Hyung Jin Cho, In Kyu Lee, Yoon Suk Lee, Sang Seob Yun, Sun Cheol Park, Jang Yong Kim, Chul Seung Lee
European Journal of Surgical Oncology.2022; 48(6): 1384. CrossRef
Racial disparities in cancer-associated thrombosis
Tatini Datta, Ann Brunson, Anjlee Mahajan, Theresa Keegan, Ted Wun
Blood Advances.2022; 6(10): 3167. CrossRef
Coagulation and Aging: Implications for the Anesthesiologist
Sarina L. Tschan, Daniel Bolliger
Current Anesthesiology Reports.2021; 11(4): 387. CrossRef
Perioperative Short Term Prophylaxis against Deep Vein Thrombosis after Major Abdominal Cancer Surgery: Retrospective Cohort Study
Nuray Colapkulu-Akgul, Ibrahim Ali Ozemir, Damla Beyazadam, Orhan Alimoglu
Vascular Specialist International.2021;[Epub] CrossRef
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key, Alok A. Khorana, Nicole M. Kuderer, Kari Bohlke, Agnes Y.Y. Lee, Juan I. Arcelus, Sandra L. Wong, Edward P. Balaban, Christopher R. Flowers, Charles W. Francis, Leigh E. Gates, Ajay K. Kakkar, Mark N. Levine, Howard A. Liebman, Margaret A. T
Journal of Clinical Oncology.2020; 38(5): 496. CrossRef
Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY
Cecilia Becattini, Ugo Pace, Fabio Rondelli, Paolo Delrio, Graziano Ceccarelli, Michela Boncompagni, Luigina Graziosi, Adriana Visonà, Damiano Chiari, Giampiero Avruscio, Stefania Frasson, Gualberto Gussoni, Alessia Biancafarina, Giuseppe Camporese, Annib
European Journal of Internal Medicine.2020; 72: 53. CrossRef
Incidence of postsurgical pulmonary embolism and deep venous thrombosis: a single-center retrospective observational study
Hitomi Otsuka, Makoto Izumi, Eriko Ota, Noriaki Mochizuki
JA Clinical Reports.2020;[Epub] CrossRef
The impact of hereditary thrombophilia on the incidence of postoperative venous thromboembolism in colorectal cancer patients: a prospective cohort study
Jan Ulrych, Tomas Kvasnicka, Vladimir Fryba, Martin Komarc, Ivana Malikova, Radka Brzezkova, Jan Kvasnicka Jr, Zdenek Krska, Jan Briza, Jan Kvasnicka
European Surgery.2019; 51(1): 5. CrossRef
Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis
Mao Li, Qiang Guo, Weiming Hu
Thrombosis Research.2019; 173: 48. CrossRef
The prevalence of venous thromboembolism in rectal surgery: a systematic review and meta-analysis
Joshua W. Hayes, Éanna J. Ryan, Patrick A. Boland, Ben Creavin, Michael E. Kelly, David Beddy
International Journal of Colorectal Disease.2019; 34(5): 849. CrossRef
European guidelines on perioperative venous thromboembolism prophylaxis
Sibylle Kozek-Langenecker, Christian Fenger-Eriksen, Emmanuel Thienpont, Giedrius Barauskas
European Journal of Anaesthesiology.2018; 35(2): 116. CrossRef
The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery
Geoffrey Bellini, Annabelle Teng, Nisha Kotecha, Elie Sutton, Chun Kevin Yang, Michael Passeri, David Y. Lee, Keith Rose
Journal of Surgical Research.2016; 205(2): 279. CrossRef

13,360 View
184 Download
18 Web of Science
18 Crossref

Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells: Mi Hyun Kang, Sung Ung Moon, Ji Hea Sung, Jin Won Kim, Keun Wook Lee, Hye Seung Lee, Jong Seok Lee, Jee Hyun Kim; Cancer Res Treat. 2016;48(1):355-364. Published online March 5, 2015; DOI: https://doi.org/10.4143/crt.2014.260

Abstract PDF PubReader ePub

Purpose
HM781-36B is a novel and irreversible pan-human epidermal growth factor receptor (HER) inhibitor with TEC cytoplasmic kinase inhibition. The aim of this study is to evaluate the antitumor activity and mechanism of action for HM781-36B in CRC cell lines.
Materials and Methods
The CRC cell lines were exposed to HM781-36B and/or oxaliplatin (L-OHP), 5-fluorouracil (5-FU), SN-38. The cell viability was examined by Cell Titer-Glo luminescent cell viability assay kit. Change in the cell cycle and protein expression was determined by flow cytometry and immunoblot analysis, respectively. Synergism between 2 drugs was evaluated by the combination index.
Results
The addition of HM781-36B induced potent growth inhibition in both DiFi cells with EGFR overexpression and SNU-175 cells (IC50 = 0.003 and 0.005 M, respectively). Furthermore, HM781-36B induced G1 arrest of the cell cycle and apoptosis, and reduced the levels of HER family and downstream signaling molecules, pERK and pAKT, as well as nonreceptor/cytoplasmic tyrosine kinase, BMX. The combination of HM781-36B with 5-FU, L-OHP, or SN-38 showed an additive or synergistic effect in most CRC cells.
Conclusion
These findings suggest the potential roles of HM781-36B as the treatment for EGFR-overexpressing colon cancer, singly or in combination with chemotherapeutic agents. The role of BMX expression as a marker of response to HM781-36B should be further explored.

Citations

Citations to this article as recorded by

Synthesis, cytotoxic evaluation, and in silico studies of novel benzenesulfonamide-thiazolidinone derivatives against colorectal carcinoma
Belma Zengin Kurt, Mustafa Gökçe, Halil Şenol, Dilek Öztürk Civelek, Gülnur Dandin, Isil Gazioglu
Journal of Molecular Structure.2025; 1321: 140153. CrossRef
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Meng Hu, Congying Zhong, Jiabing Wang, JinQin Chen, Tao Zhou
Frontiers in Immunology.2024;[Epub] CrossRef
Piperazine-derived ionizable lipids for enhanced mRNA delivery and cancer immunotherapy
Kai Xu, Yujia Xu, Jin Sun, Xinwei Cheng, Chenxi Lu, Wenzhong Chen, Bingfang He, Tianyue Jiang
Nano Research.2024; 17(8): 7357. CrossRef
A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma
Jing Yang, Yanfei Yang, Yuquan Wei, Xiawei Wei
Frontiers of Medicine.2023; 17(2): 275. CrossRef
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina C. Garassino, John V. Heymach, Mark A. Socinski, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, Xiuning L
Journal of Thoracic Oncology.2023; 18(8): 1031. CrossRef
Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
Xiuning Le, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, Gajanan Bhat, Francois Lebel, John V. Heymach, Mark A. Socinski
Journal of Clinical Oncology.2022; 40(7): 710. CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
Cancers.2020; 12(11): 3249. CrossRef
miRDRN—miRNA disease regulatory network: a tool for exploring disease and tissue-specific microRNA regulatory networks
Hsueh-Chuan Liu, Yi-Shian Peng, Hoong-Chien Lee
PeerJ.2019; 7: e7309. CrossRef
Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc
Yufang Zuo, Dongyan Yang, Yin Yu, Mei Xiang, Haiwen Li, Jun Yang, Jingjing Li, Danxian Jiang, Hechao Zhou, Zumin Xu, Zhonghua Yu
Molecular Medicine Reports.2017;[Epub] CrossRef
FXR1 is elevated in colorectal cancer and acts as an oncogene
Xin Jin, Bo Zhai, Taishi Fang, Xiaohui Guo, Lishan Xu
Tumor Biology.2016; 37(2): 2683. CrossRef

16,348 View
198 Download
11 Web of Science
10 Crossref

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations: Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo; Cancer Res Treat. 2015;47(4):630-637. Published online February 16, 2015; DOI: https://doi.org/10.4143/crt.2014.244

Abstract PDF PubReader ePub

Purpose
Platinum-based doublet chemotherapy is the treatment of choice for patients with non-small cell lung cancer (NSCLC); however, the role of a platinum-based doublet as second-line therapy after failure of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for NSCLC patients has not yet been elucidated. The purpose of this study was to compare the clinical efficacy of pemetrexed versus a platinum-based doublet as second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patients with EGFR mutations. Materials and Methods We designed a multicenter retrospective cohort study of 314 NSCLC patients with EGFR mutations who received an EGFR TKI as first-line palliative chemotherapy. Our analysis included 83 patients who failed EGFR TKI therapy and received second-line cytotoxic chemotherapy.
Results
Forty-six patients were treated using a platinum-based doublet and 37 patients were treated using singlet pemetrexed. The overall response rates of patients receiving a platinum-based doublet and patients receiving pemetrexed were17.4% and 32.4%, respectively (p=0.111). The median progression-free survival (PFS) of patients receiving pemetrexed was significantly longer than that of patients receiving a platinum-based doublet (4.2 months vs. 2.7 months, respectively; p=0.008). The hazard ratio was 0.54 (95% confidence interval, 0.34 to 0.86; p=0.009). Conclusion Our retrospective analysis found that second-line pemetrexed singlet therapy provided significantly prolonged PFS compared to second-line platinum-based doublet chemotherapy for NSCLC patients with EGFRmutations who failed first-line EGFR TKI. Conduct of prospective studies for confirmation of our results is warranted.

Citations

Citations to this article as recorded by

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Chen, Chien-Feng Li
PLOS ONE.2024; 19(5): e0303046. CrossRef
Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo
Cancer Research and Treatment.2023; 55(4): 1134. CrossRef
A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li
Medicine.2020; 99(29): e21170. CrossRef
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun,
Cancer Research and Treatment.2019; 51(2): 718. CrossRef
Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism
Bo Li, Junkai Zhang, Ya Su, Yiling Hou, Zhenguo Wang, Lin Zhao, Shengkai Sun, Hao Fu
Molecular Medicine Reports.2019;[Epub] CrossRef
Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
Pteridines.2019; 30(1): 171. CrossRef
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis
Kathleen M. Aguilar, Katherine B. Winfree, Catherine E. Muehlenbein, Yajun Emily Zhu, Thomas Wilson, Stewart Wetmore, Eric S. Nadler
Advances in Therapy.2018; 35(11): 1905. CrossRef
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
Hyungjin Kim, Chang Min Park, Bhumsuk Keam, Sang Joon Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jin Mo Goo, Fan Yang
PLOS ONE.2017; 12(11): e0187500. CrossRef
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature
Caicun Zhou, Luan Di Yao
Journal of Thoracic Oncology.2016; 11(2): 174. CrossRef
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
Federico Cappuzzo, Alessandro Morabito, Nicola Normanno, Paolo Bidoli, Alessandro Del Conte, Laura Giannetta, Agnese Montanino, Francesca Mazzoni, Roberta Buosi, Marco Angelo Burgio, Giulio Cerea, Rita Chiari, Diego Cortinovis, Giovanna Finocchiaro, Luisa
Lung Cancer.2016; 99: 31. CrossRef
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
Jordi Remon, Benjamin Besse
ESMO Open.2016; 1(4): e000081. CrossRef
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Su Jin Lee, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Lung Cancer.2015; 90(2): 261. CrossRef

15,132 View
165 Download
22 Web of Science
12 Crossref

p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines: Sung-Ung Moon, Jin Won Kim, Ji Hea Sung, Mi Hyun Kang, Se-Hyun Kim, Hyun Chang, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee; Cancer Res Treat. 2015;47(3):501-508. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2014.054

Abstract PDF PubReader ePub

Purpose
p21-activated kinases (PAKs) are involved in cytoskeletal reorganization, gene transcription, cell proliferation and survival, and oncogenic transformation. Therefore, we hypothesized that PAK expression levels could predict the sensitivity of pancreatic cancer cells to gemcitabine treatment, and PAKs could be therapeutic targets.
Materials and Methods
Cell viability inhibition by gemcitabine was evaluated in human pancreatic cancer cell lines (Capan-1, Capan-2, MIA PaCa-2, PANC-1, Aspc-1, SNU-213, and SNU-410). Protein expression and mRNA of molecules was detected by immunoblot analysis and reverse transcription polymerase chain reaction. To define the function of PAK4, PAK4 was controlled using PAK4 siRNA.
Results
Capan-2, PANC-1, and SNU-410 cells were resistant to gemcitabine treatment. Immunoblot analysis of signaling molecules reported to indicate gemcitabine sensitivity showed higher expression of PAK4 and lower expression of human equilibrative nucleoside transporter 1 (hENT1), a well-known predictive marker for gemcitabine activity, in the resistant cell lines. Knockdown of PAK4 using siRNA induced the upregulation of hENT1. In resistant cell lines (Capan-2, PANC-1, and SNU-410), knockdown of PAK4 by siRNA resulted in restoration of sensitivity to gemcitabine.
Conclusion
PAK4 could be a predictive marker of gemcitabine sensitivity and a potential therapeutic target to increase gemcitabine sensitivity in pancreatic cancer.

Citations

Citations to this article as recorded by

Synthesis of a Gemcitabine Prodrug and its Encapsulation into Polymeric Nanoparticles for Improved Therapeutic Efficacy
Kajal Kaliya, Neha Bhardwaj, Ruchika, Ankit Saneja
ChemMedChem.2025;[Epub] CrossRef
Knockout of p21-Activated Kinase 4 Stimulates MHC I Expression of Pancreatic Cancer Cells via an Autophagy-Independent Pathway
Yi Ma, Chelsea Dumesny, Li Dong, Ching-Seng Ang, Mehrdad Nikfarjam, Hong He
Cancers.2025; 17(3): 511. CrossRef
Biological role of the PAK4 signaling pathway: A prospective therapeutic target for multivarious cancers
Md. Mozibullah, Md. Junaid
Arabian Journal of Chemistry.2023; 16(1): 104438. CrossRef
Expression Patterns of PAK4 and PHF8 Are Associated with the Survival of Gallbladder Carcinoma Patients
Ae Ri Ahn, Maryam Karamikheirabad, Min Su Park, Junyue Zhang, Hyun Sun Kim, Ji Su Jeong, Kyoung Min Kim, Ho Sung Park, Kyu Yun Jang
Diagnostics.2023; 13(6): 1149. CrossRef
PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways
Charudatt Samant, Ramesh Kale, Anand Bokare, Mahip Verma, K. Sreedhara Ranganath Pai, Mandar Bhonde
Biochemistry and Biophysics Reports.2023; 35: 101544. CrossRef
A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine
Hong He, Chelsea Dumesny, Ching-Seng Ang, Li Dong, Yi Ma, Jun Zeng, Mehrdad Nikfarjam
Translational Oncology.2022; 16: 101329. CrossRef
Synthesis and biological evaluation of 7H-pyrrolo [2,3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors
Cong Wang, Jiawei Xia, Yan Lei, Rui Lu, Mingliang Zhang, He Lv, Qianqian Hong, Tao Lu, Yadong Chen, Hongmei Li
Bioorganic & Medicinal Chemistry.2022; 60: 116700. CrossRef
A Study on the Effect of the Substituent against PAK4 Inhibition Using In Silico Methods
Hye Ree Yoon, Chong Chul Chai, Cheol Hee Kim, Nam Sook Kang
International Journal of Molecular Sciences.2022; 23(6): 3337. CrossRef
Alloferon Affects the Chemosensitivity of Pancreatic Cancer by Regulating the Expression of SLC6A14
Hyejung Jo, Dahae Lee, Cheolhyeon Go, Yoojin Jang, Suhyun Bae, Tomoyo Agura, Jiye Hong, Dongmin Kang, Yejin Kim, Jae Seung Kang
Biomedicines.2022; 10(5): 1113. CrossRef
The significance of PAK4 in signaling and clinicopathology: A review
Xinbo Yu, Changwei Huang, Jiyuan Liu, Xinyu Shi, Xiaodong Li
Open Life Sciences.2022; 17(1): 586. CrossRef
The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma
Yi Ma, Mehrdad Nikfarjam, Hong He
Cancer Letters.2022; 548: 215868. CrossRef
p21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond
Xiaodong Li, Feng Li
Cancers.2022; 14(19): 4736. CrossRef
Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment
Lizhou Xu, Farid N. Faruqu, Yau M. Lim, Kee Y. Lim, Revadee Liam-Or, Adam A. Walters, Paul Lavender, David Fear, Claire M. Wells, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
Biomaterials.2021; 264: 120369. CrossRef
RETRACTED ARTICLE: Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression
Shasha Bi, Yan Wang, Hu Feng, Qingchang Li
Cell Cycle.2020; 19(7): 801. CrossRef
p21-Activated Kinases in Thyroid Cancer
Luis Bautista, Christina M Knippler, Matthew D Ringel
Endocrinology.2020;[Epub] CrossRef
Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases
Rakesh Kumar, Aswathy Mary Paul, Ravikumar Amjesh, Bijesh George, M. Radhakrishna Pillai
Cancer and Metastasis Reviews.2020; 39(3): 583. CrossRef
Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer
Kai Wang, Graham S. Baldwin, Mehrdad Nikfarjam, Hong He
American Journal of Physiology-Gastrointestinal and Liver Physiology.2019; 316(5): G632. CrossRef
PAK4 Pathway as a Potential Therapeutic Target in Pancreatic Cancer
Kiruthikah Thillai, Debashis Sarker, Claire Wells
Future Oncology.2018; 14(7): 579. CrossRef
p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation
Kai Wang, Graham S Baldwin, Mehrdad Nikfarjam, Hong He
World Journal of Gastroenterology.2018; 24(33): 3709. CrossRef
Structure, biochemistry, and biology of PAK kinases
Rakesh Kumar, Rahul Sanawar, Xiaodong Li, Feng Li
Gene.2017; 605: 20. CrossRef
Prognostic value of p21‐activated kinase 4 in resected pancreatic cancer
Sehhoon Park, Jin Won Kim, Haeryoung Kim, Ji‐Won Kim, Yu Jung Kim, Keun‐Wook Lee, Jee Hyun Kim, Jai Hwan Kim, Jin‐Hyeok Hwang, Young Rok Choi, Jai Young Cho, Yoo‐Seok Yoon, Ho‐Seong Han
APMIS.2017; 125(8): 699. CrossRef
Pdx1-Cre-driven conditional gene depletion suggests PAK4 as dispensable for mouse pancreas development
Miao Zhao, Parisa Rabieifar, Tânia D. F. Costa, Ting Zhuang, Audrey Minden, Matthias Löhr, Rainer Heuchel, Staffan Strömblad
Scientific Reports.2017;[Epub] CrossRef
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine
Kai Wang, Nhi Huynh, Xiao Wang, Graham Baldwin, Mehrdad Nikfarjam, Hong He
International Journal of Oncology.2017;[Epub] CrossRef
S-1 plus nab -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model
Masaya Suenaga, Suguru Yamada, Tsutomu Fujii, Chie Tanaka, Mitsuro Kanda, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
Journal of Surgical Oncology.2016; 113(4): 413. CrossRef
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
Dannel Yeo, Hong He, Oneel Patel, Andrew M. Lowy, Graham S. Baldwin, Mehrdad Nikfarjam
BMC Cancer.2016;[Epub] CrossRef
PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway
Xiang-Rong Shu, Jing Wu, He Sun, Li-Qun Chi, Jin-Huan Wang
Diagnostic Pathology.2015;[Epub] CrossRef

16,547 View
185 Download
35 Web of Science
26 Crossref

Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era: Nae Yu Kim, Jong Mu Sun, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jin-Wook Kim, Sook-Hyang Jeong, Jong Seok Lee; Cancer Res Treat. 2010;42(4):203-209. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.203

Abstract PDF PubReader ePub

Purpose

Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses.

Materials and Methods

The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS.

Results

Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95% CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95% CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP.

Conclusion

Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.

Citations

Citations to this article as recorded by

circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR‐338‐5p/IL‐7 pathway
Siyu Zhang, Jun Ma, Tingdong Yu, Zhengrui Song, Wan Yee Lau, Yong Zha
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Inhibition of mycobacteria proliferation in macrophages by low cisplatin concentration through phosphorylated p53-related apoptosis pathway
Jiajia Bao, Yonglin He, Chun Yang, Nan Lu, Anlong Li, Sijia Gao, Felycia Fernanda Hosyanto, Jialing Tang, Junzhuo Si, Xia Tang, Huichao Fu, Lei Xu, Harish Chandra
PLOS ONE.2023; 18(1): e0281170. CrossRef
A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma
Yao‐Chung Liu, Chien‐Wei Su, Po‐Shen Ko, Rheun‐Chuan Lee, Chia‐Jen Liu, Yi‐Hsiang Huang, Jyh‐Pyng Gau, Jin‐Hwang Liu
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 19. CrossRef
A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy
Vincent Manceau, Xavier Palard, Yan Rolland, March Pracht, Samuel Le Sourd, Sophie Laffont, Karim Boudjema, Astride Lievre, Habiba Mesbah, Laure-Anne Haumont, Laurence Lenoir, Vanessa Brun, Thomas Uguen, Julien Edeline, Etienne Garin
European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(10): 1731. CrossRef
Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1
Jun Qin, Meng Luo, Haixin Qian, Wei Chen
Gene.2014; 538(2): 342. CrossRef
The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines
EUN-YOUNG MIN, IN-HYE KIM, JUNGIM LEE, EUN-YOUNG KIM, YOUN-HEE CHOI, TAEK-JEONG NAM
International Journal of Oncology.2014; 45(1): 47. CrossRef
The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation
Vasilis P. Androutsopoulos, Demetrios A. Spandidos
The Journal of Nutritional Biochemistry.2013; 24(2): 496. CrossRef
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
Hiroki Nishikawa, Yukio Osaki, Ryuichi Kita, Toru Kimura
Cancers.2012; 4(1): 165. CrossRef

9,838 View
55 Download
8 Crossref

An Evaluation of Nutrition Support for Terminal Cancer Patients at Teaching Hospitals in Korea: Do Yeun Kim, Sang Min Lee, Kyoung Eun Lee, Hye Ran Lee, Jee Hyun Kim, Keun-Wook Lee, Jong Seok Lee, Soon Nam Lee; Cancer Res Treat. 2006;38(4):214-217. Published online December 31, 2006; DOI: https://doi.org/10.4143/crt.2006.38.4.214

Abstract PDF PubReader ePub

Purpose

We wanted to analyze the use of nutrition support for terminal cancer patients, the effect of discussing withdrawal of nutrition support and do-not-resuscitate (DNR) consent on the use of intravenous nutrition during the patient's last week of life and at the time of death.

Materials and Methods

The study involved 362 patients with terminal cancer from four teaching hospitals, and they all died between January 1 2003 and December 31 2005. The basic demographic data, the use of intravenous nutrition during the patient's last week of life and at death, discussion of terminal nutrition withdrawal and DNR consent were evaluated.

Results

In the week before death, the patients received artificial nutrition such as total parenteral nutrition (31%), intravenous albumin infusion (25%), and feeding tube placements (9%). A discussion concerning withdrawal of nutrition support was limited to 25 (7%) patients. DNR consent was obtained from 294 (81%) patients. None of the patients were directly involved in any of these decisions. The discussion about withdrawal of terminal nutrition and DNR consent with the patient's surrogates did not have any effect on reducing the use of parenteral nutrition.

Conclusion

The majority of patients dying of terminal cancer were still given potentially futile nutritional support. Modern clinical guidelines and ethical education about nutritional support at the end of life care is urgently needed in Korean medical practice to provide proper administration of terminal nutrition for end of life care.

Citations

Citations to this article as recorded by

Report of the Lancet Commission on the Value of Death: bringing death back into life
Libby Sallnow, Richard Smith, Sam H Ahmedzai, Afsan Bhadelia, Charlotte Chamberlain, Yali Cong, Brett Doble, Luckson Dullie, Robin Durie, Eric A Finkelstein, Sam Guglani, Melanie Hodson, Bettina S Husebø, Allan Kellehear, Celia Kitzinger, Felicia Marie Kn
The Lancet.2022; 399(10327): 837. CrossRef
A National Study of Life-Sustaining Treatments in South Korea: What Factors Affect Decision-Making?
So-Youn Park, Bomyee Lee, Jeong Yeon Seon, In-Hwan Oh
Cancer Research and Treatment.2021; 53(2): 593. CrossRef
The Trend of Aggressive Treatments in End-of-Life Care for Older People With Dementia After a Policy Change in Taiwan
Ying Hsin Hsu, Ming Yueh Chou, Hsiu-Min Chen, Wei-Cheng Chang, Che Sheng Chu, Yu-Chun Wang, Chiao-Lin Hsu, Chih-Kuang Liang, Ching-Chih Lee, Yu Te Lin
Journal of the American Medical Directors Association.2020; 21(6): 858. CrossRef
Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
Cancer Research and Treatment.2020; 52(3): 917. CrossRef
Nutrition Intervention through Interdisciplinary Medical Treatment in Hospice Patients: From Admission to Death
Hyelim Kang, Yu Jin Yang, Juyeon Park, Gyu Jin Heo, Jeong-Im Hong, Hye-Jin Kim
Clinical Nutrition Research.2018; 7(2): 146. CrossRef
Evidence for overuse of medical services around the world
Shannon Brownlee, Kalipso Chalkidou, Jenny Doust, Adam G Elshaug, Paul Glasziou, Iona Heath, Somil Nagpal, Vikas Saini, Divya Srivastava, Kelsey Chalmers, Deborah Korenstein
The Lancet.2017; 390(10090): 156. CrossRef
A Randomized Phase II Study To Assess the Effectiveness of Fluid Therapy or Intensive Nutritional Support on Survival in Patients with Advanced Cancer Who Cannot be Nourished via Enteral Route
So Yeon Oh, Hyun Jung Jun, Sung Jae Park, In Ki Park, Ga Jin Lim, Yeonsil Yu, Sung-Ja Cho, Aeran Song
Journal of Palliative Medicine.2014; 17(11): 1266. CrossRef
Evaluation of parenteral nutritional support in the surgical and medical wards of a referral teaching hospital
Samaneh Bairami, Sepideh Elyasi, Hossein Khalili, Saeed Reza Jamali-Moghadam
DARU Journal of Pharmaceutical Sciences.2012;[Epub] CrossRef
Awareness and Attitude Change after End-of-Life Care Education for Medical Students
Hyun Kyung Kim, Eunmi Nam, Kyoung Eun Lee, Soon Nam Lee
The Korean Journal of Hospice and Palliative Care.2012; 15(1): 30. CrossRef
Charactersitics and issues of guideline to withdrawal of a life-sustaining therapy
Younsuck Koh, Dae-Seog Heo, Young Ho Yun, Jeong-Lim Moon, Hyoung Wook Park, Ji Tae Choung, Hyo Sung Jung, Bark Jang Byun, Yoon-Seong Lee
Journal of the Korean Medical Association.2011; 54(7): 747. CrossRef
Nasogastric feeding at the end of life: A virtue ethics approach
Lalit Krishna
Nursing Ethics.2011; 18(4): 485. CrossRef
Chinese Familial Tradition and Western Influence: A Case Study in Singapore on Decision Making at the End of Life
Zheng Jie Marc Ho, Lalit Kumar Radha Krishna, Chung Pheng Alethea Yee
Journal of Pain and Symptom Management.2010; 40(6): 932. CrossRef

10,241 View
71 Download
12 Crossref

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregional Esophageal Cancer: Gyeong Won Lee, Jung Hun Kang, Hun Gu Kim, In Gyu Hwang, Ki Shik Shim, Seok Hyun Kim, Won Sep Lee, Woon Tae Jung, Ok Jae Lee, Jung Hyeun Cho, Joung Soon Jang, Kyu Yong Chae, Jong Seok Lee; Cancer Res Treat. 2001;33(6):489-494. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.489

Abstract PDF

PURPOSE
The object of this study is to evaluate the efficacy and toxicity of induction chemotherapy followed by concomitant chemoradiotherapy in locoregional esophageal cancer.
MATERIALS AND METHODS
Between December 1992 and December 1999, 43 patients with locoregional esophageal cancer were enrolled in this phase II trial. Patients were treated with 2-cycles of induction chemotherapy followed by concomitant chemoradiotherapy. F-P chemotherapy consists of 1,000 mg/m2/Day of 5-FU as continuous infusion on day 1~5 and 80 mg/m2 of cisplatin as an intravenous bolus on day 1 and was repeated every 3~4 weeks. All patients received 60 Gy of external beam radiation concomitantly with F-P chemotherapy; intraluminal brachytherapy was added in 12 patients. A total of 4 cycles of chemotherapy were delivered. No further treatment was planned in patients who achieved complete remission after completion of the treatment.
RESULTS
Among the 43 patients entered, 35 patients completed the protocol. Of the 35 evaluable patients, 12 patients (34%) achieved complete response and 13 patients (37%) achieved partial response. In 26 of 33 patients, dysphagia was improved. At a median follow-up of 22 months, the 2-year and 5-year survival rates were 39% and 19%, respectively. The median survival duration of the complete responder group was 69 months (4~100 months) and the 2-year survival rate of the complete responder group was 82%. Toxicities were tolerable, comprised of mucositis and cytopenia.
CONCLUSION
Induction chemotherapy followed by concurrent chemoradiotherapy in locoregional esophageal cancer is well tolerated and effective.

Citations

Citations to this article as recorded by

A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis
Yang Li, Qingwu Du, Xiaoying Wei, Zhoubo Guo, Tongda Lei, Yanqi Li, Dong Han, Xiaoyue Wu, Kunning Zhang, Tian Zhang, Xi Chen, Jie Dong, Baozhong Zhang, Hui Wei, Wencheng Zhang, Qingsong Pang, Ping Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Salvage Esophagectomy for Locoregional Failure After Chemoradiotherapy in Patients With Advanced Esophageal Cancer
Changhoon Yoo, Ji Hyun Park, Dok Hyun Yoon, Seung-Il Park, Hyeong Ryul Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho June Song, Ho-Young Song, Ji Hoon Shin, Kyung-Ja Cho, Yong Hee Kim, Sung-Bae Kim
The Annals of Thoracic Surgery.2012; 94(6): 1862. CrossRef

4,511 View
32 Download
2 Crossref

Combination Chemotherapy with Mitomycin C, Vinorelbine, and Cisplatin (MVrP) in Patients with Advanced Non-Small Cell Lung Cancer: Hun Gu Kim, Gyeong Won Lee, Dae Hwan Lee, In Gyu Hwang, Ki Shik Shim, Won Sup Lee, Jong Deog Lee, Joung Soon Jang, Young Sil Hwang, Jong Seok Lee; Cancer Res Treat. 2001;33(5):377-384. Published online October 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.5.377

Abstract PDF: PURPOSE
A phase II study was conducted in patients with advanced non-small cell lung cancer (NSCLC) in order to evaluate the efficacy and toxicity of the combination chemotherapy regimen of mitomycin C, vinorelbine, and cisplatin (MVrP).
MATERIALS AND METHODS
Between June 1996 and December 2000, fifty-nine patients with unresectable stage IIIB to IV, pathologically documented NSCLC were enrolled in this study. One cycle consisted of mitomycin C 10 mg/m2 i.v. day 1, vinorelbine 30 mg/m2 i.v. days 1 & 15, and cisplatin 80 mg/m2 i.v day 1 and the next cycle consisted of vinorelbine 30 mg/m2 i.v. days 29 & 43, and cisplatin 80 mg/m2 i.v day 29. Each cycle was alternated and treatments were repeated every 8 weeks.
RESULTS
We were able to evaluate fifty-three of 59 patients. Objective responses were seen in 22 (41.5%) patients (CR 0%, PR 41.5%). The median duration of response was 13.7 weeks and the median time to progression was 17.7 weeks. The median overall survival was 45.6 weeks. There was a significantly longer survival seen in responders (p=0.041). The toxicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION
This study suggests that a combination regimen of mitomycin C, vinorelbine, and cisplatin is relatively effective and well tolerated for the treatment of advanced NSCLC.

4,333 View
27 Download

BACOD/EISHAP Alternating Combination Chemotherapy for Intermediate and High Grade Non-Hodgkin's Lymphoma: Jung Hun Kang, Young Ho Park, Soo Jin Kim, Ji Chul Yun, Gyeong Won Lee, Hun Gu Kim, In Gyu Hwang, Won Sup Lee, Joung Soon Jang, Jong Seok Lee; J Korean Cancer Assoc. 2000;32(4):793-800.

Abstract PDF: PURPOSE
We conducted a phase II study to determine the antitumor activity of BACOD/EISHAP alternating 9-drug chemotherapy in previously untreated patients with intermediate or high grade non-Hodgkin's lymphoma (NHL).
MATERIALS AND METHODS
Intermediate or high grade non-Hodgkin's lymphoma patients were treated with BACOD/EISHAP (bleomycin, doxorubicin, cyclophosphamide, vincristine, dexame thasone/etoposide, ifosfamide, high dose cytarabine, cisplatin, dexamethasone) alternating com bination chemotherapy. Stage I and IIA lymphoma patients were excluded. BACOD/EISHAP alternating chemotherapy was given to the eligible patients every 3 weeks/4 weeks respectively.
RESULTS
Between April, 1995 and December, 1997, among 25 eligible patients, 19 patients were evaluable for response. Six patients could not be evaluated for response because of follow-up loss within 2 cycles of chemotherapy. Complete response (CR) was achieved in 12 patients (63%) after BACOD/EISHAP alternating combination chemotherapy. With a follow-up period of 41 months (25~57 months), the disease free survival did not reach median (4~47 months) and 3-year disease free survival rate was 75%. Major toxicity was marrow suppression and the incidence of severe leukopenia (WBC<2,000/mm3) and thromobocytopenia (<25,000/mm3) were 15%, 5%, respectively. No treatment-related death was observed. For non-hematologic toxicities, nausea and vomiting were observed in 65% of patients, stomatitis in 25%, peripheral neuropathy in 20%.
CONCLUSION
BACOD/EISHAP alternating chemotherapy was feasible with acceptable toxicities. The 63% complete response rate was comparable to other regimens but 75% 3year disease-free survival rate was encouraging. Further evaluation of this regimen is warranted.

3,020 View
27 Download

Effect of Granisetron Plus Dexamethasone in the Prevention of Delayed Nausea and Vomiting: Jeong Woo Shim, Yong Seop Lee, Heung Up Kim, Geong Won Jung, Yeong Ho Park, Se Ho Chang, Jin Yong Whang, Jeong Soon Jang, Jong Seok Lee; J Korean Cancer Assoc. 1997;29(4):690-699.

Abstract PDF: BACKGROUND
Granisetron, a new 5-HT3 receptor antagonist, was reported as a highly effective antiemetics, especially in combination with dexamethasone, in the prevention of acute emesis induced by cisplatin. But there is lack of data about effectiveness in the prevention of delayed emesis. In this study, the efficacy of granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin was evaluated.
MATERIALS AND METHODS
Sixty-four patients who were to receive high-dose cisplatin containing chemotherapy regimen were enrolled in this study. They were received 20 mg of dexamethasone and 3 mg of granisetron at 30 min and 10 minutes prior to cisplatin infusion, respectively. They were monitored for 5 days, first 24 hours for acute nausea/ vomiting and the subsequent 4 days for delayed nausea/vomiting. Antiemetic effect of granisetron was evaluated according to the criteria of Italian Group of Antiemetic Research.
RESULTS
Control of delayed nausea and vomiting was achieved in 58% and 84%, respectively. Eastern Cooperative Oncology Group performance status was a statistically significant prognostic factor for control of acute vomiting and delayed nausea/vomiting. There were no stastically significant differences between control of delayed nausea/ vomiting and other prognostic factors, including sex, age, and prior history of cisplatin therapy. The antiemetic effect was greater in the patients who had controled acute nausea/ vomiting than those who had not.
CONCLUSION
Granisetron plus dexamethasone is an excellent regimen in the control of not only acute emesis but also delayed emesis induced by high-dose cisplatin chemotherapy.

2,902 View
17 Download

First
Prev
Page of 1
Next
Last

Search